FIGURE 4.

Spectrum of altered genes in clinical specimens from patients with hematological malignancies, by disease type. (A–E) Number of somatic alterations in patients diagnosed with (A) acute myeloid leukemia (AML), (B) acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL), (C) B‐cell non‐Hodgkin lymphoma (B‐NHL), (D) T/natural killer‐cell non‐Hodgkin lymphoma (T/NK‐NHL), and (E) multiple myeloma (MM). Stars represent the evidence level assigned to genes according to the Japanese Society of Hematology Genome Guideline in each disease type. In case of >1 alteration type detected, they are considered multiple for tumor suppressor or functionally unknown genes, whereas only one major alteration type is counted for oncogenes. CNA, copy number alteration; SV, structural variation